ArticleJournal of cellular and molecular medicine2024
Pharmacological Network Analysis of the Functions and Mechanism of Quercetin From Jisuikang (JSK) in Spinal Cord Injury (SCI).
Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neuroinflammation, especially microglia/macrophage activation, is a hallmark of spinal cord injury (SCI). Jisuikang (JSK) is a clinical experiential Chinese herbal formula for SCI therapy containing Huangqi (Astragali Radix), Danggui (Angelica sinensis Radix), Chishao (Paeoniae Radix Rubra), Dilong (earthworm, Pheretima aspergillum), Chuanxiong (Chuanxiong Rhizoma), Taoren (Persicae Seman) and Honghua (Carthami Flos). Eighteen active ingredients in 6 herbs of JSK were found to be correlated with inflammation, spinal injury and other diseases. These 18 active ingredients target 5464 genes according to the PubChem database. Through comparing differentially expressed genes between SCI and normal samples using GSE datasets, 50 hub genes were identified. These hub-genes were enriched in oxidative stress response and inflammation response. The herb-compound-target, herb-compound-signalling and compound-target-signalling networks were generated and quercetin was identified as the hub compound. A concentration of 25 μM quercetin showed no cytotoxicity but significantly protected microglial cells from LPS-induced inhibition of cell viability. LPS stimulation elevated the levels of iNOS, IL-1β and TNF-α but decreased IL-10 levels, whereas quercetin significantly attenuated LPS-induced alterations in these factors. Moreover, quercetin targeted gene, IL1R1 was reduced by quercetin as predicted. Overexpression of IL1R1 further increased LPS-induced inflammation, which could be partly reversed by quercetin treatment. In vivo, quercetin improved histopathological alterations, inflammation and promoted M2 macrophage polarisation post-injury, whereas IL1R1 overexpression partially attenuated the beneficial effects of quercetin on the rat SCI model. Collectively, quercetin, the main ingredient compound of JSK, protects against LPS-induced cell viability inhibition and cellular inflammation, which could be partially attenuated by IL1R1 overexpression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.